EZH2 and triple-negative breast carcinoma: In EZH2-dependent triple-negative breast cancer cells, the newly developed EZH2 specific degrader MS1943 reduced cell proliferation and induced apoptosis effectively in contrast to selective inhibitors of the enzymatic activity of EZH2 [46].